Back to search results
NCT06108102

International Post-Stroke Epilepsy Research Repository

Enrolling by Invitation
Not specifiedAges 18+Observational
Yale University
~8,000 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mortality (modified Rankin Scale = 6)
Measured over At 1 year, 2 year, and 5 year follow-up
+6 more outcomes measured

Conditions

Post Stroke Epilepsy
Post Stroke Seizure
Stroke
Epilepsy

Explore related trials

Post-Stroke EpilepsyPost-Stroke SeizureStroke

NCT06108102

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale University

    New Haven, Connecticutno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nishant K Mishra, MD PhD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Studies with minimum dataset of 100 patients
Studies comprising stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting early or late PSS with data on patient outcome measures.
Documented consent or waiver of consent following local Institutional Review Board-approved procedure.
Studies published on human subjects.
No restriction based on the date or language of publication, gender, or ethnicity.

Exclusion

Studies of patients with a prior history of seizures before the index stroke,
Studies that did not report outcome data, or are not able to share IPD.

What this trial measures

  • Mortality (modified Rankin Scale = 6)At 1 year, 2 year, and 5 year follow-up

    The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death).

  • Poor functional outcome (modified Rankin Scale 3-6)At 1 year, 2 year, and 5 year follow-up

    The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death), with 0-2 indicating a good functional outcome and 3-6 indicating a poor functional outcome.

  • Seizure frequencyAt 1 year, 2 year, and 5 year follow-up

    Number of seizures post-stroke identified clinically or based on an electroencephalogram (EEG).

  • Seizure severityAt 1 year, 2 year, and 5 year follow-up

    Defined by impaired awareness and the presence of bilateral tonic or clonic seizures.

  • Occurrence or frequency of status epilepticusAt 1 year, 2 year, and 5 year follow-up

    Status epilepticus is defined as a seizure or series of seizures lasting more than 30 minutes without recovery of consciousness based on electroencephalogram (EEG) findings.

  • Length of hospital stayAt 1 year, 2 year, and 5 year follow-up

    The duration of hospital admission for a stroke is measured in days.

  • Cognitive decline assessed on an 11-question Mini-Mental State Examination (MMSE) tool or a 30-point Montreal Cognitive Assessment (MoCA) scaleAt 1 year, 2 year, and 5 year follow-up

    MMSE is tests cognitive function. It is scored out of 30, with a score of ≤26 indicating cognitive impairment. MoCA assesses mild cognitive dysfunction. It is scored out of 30, with a score of ≤24 indicating cognitive impairment.